Roman Hakl1,2, Pavel Kuklínek3, Irena Krčmová4, Pavlína Králíčková4, Tomáš Freiberger3,5,6, Petr Janků7, Marcela Vlková3,5, Jiří Litzman3,5. 1. Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. roman.hakl@fnusa.cz. 2. Faculty of Medicine, Masaryk University, Brno, Czech Republic. roman.hakl@fnusa.cz. 3. Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. 4. Department of Clinical Immunology and Allergy, University Hospital, Hradec Kralove, Czech Republic. 5. Faculty of Medicine, Masaryk University, Brno, Czech Republic. 6. Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. 7. Department of Obstetrics and Gynecology, University Hospital Brno, Brno, Czech Republic.
Abstract
PURPOSE: Hereditary angioedema (HAE) is a rare disease caused by a C1 inhibitor (C1-INH) deficit. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal oedema attacks. Managing HAE patients in pregnancy is challenging, since there are only limited data on the safety and efficacy of various therapeutic approaches. METHODS: We present our clinical experience treating acute HAE attacks during pregnancy in six consecutive patients. RESULTS: During the pregnancies, 79 HAE attacks occurred. The most frequent were abdominal 53 (67.1%) followed by peripheral 21 (26.6%), facial 10 (12.7%), and laryngeal 10 (12.7%) oedemas; 13 (16.5%) attacks were combined. Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH). Treatment had to be repeated in 5 attacks (6.3%). All six deliveries (one caesarean section and five spontaneous vaginal deliveries) were complication free. All pregnancies went to the full term and the patients delivered healthy babies with a birth weight ranging from 2850 to 3690 g. No congenital abnormalities were detected in the neonates. No abortions occurred. CONCLUSIONS: Our results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed.
PURPOSE: Hereditary angioedema (HAE) is a rare disease caused by a C1 inhibitor (C1-INH) deficit. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal oedema attacks. Managing HAE patients in pregnancy is challenging, since there are only limited data on the safety and efficacy of various therapeutic approaches. METHODS: We present our clinical experience treating acute HAE attacks during pregnancy in six consecutive patients. RESULTS: During the pregnancies, 79 HAE attacks occurred. The most frequent were abdominal 53 (67.1%) followed by peripheral 21 (26.6%), facial 10 (12.7%), and laryngeal 10 (12.7%) oedemas; 13 (16.5%) attacks were combined. Fifty (63.3%) attacks were treated with recombinant humanC1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH). Treatment had to be repeated in 5 attacks (6.3%). All six deliveries (one caesarean section and five spontaneous vaginal deliveries) were complication free. All pregnancies went to the full term and the patients delivered healthy babies with a birth weight ranging from 2850 to 3690 g. No congenital abnormalities were detected in the neonates. No abortions occurred. CONCLUSIONS: Our results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed.
Authors: T González-Quevedo; J I Larco; C Marcos; M Guilarte; M L Baeza; S Cimbollek; M C López-Serrano; M Piñero-Saavedra; M Rubio; T Caballero Journal: J Investig Allergol Clin Immunol Date: 2016 Impact factor: 4.333
Authors: Marco Cicardi; Aleena Banerji; Francisco Bracho; Alejandro Malbrán; Bernd Rosenkranz; Marc Riedl; Konrad Bork; William Lumry; Werner Aberer; Henning Bier; Murat Bas; Jens Greve; Thomas K Hoffmann; Henriette Farkas; Avner Reshef; Bruce Ritchie; William Yang; Jürgen Grabbe; Shmuel Kivity; Wolfhart Kreuz; Robyn J Levy; Thomas Luger; Krystyna Obtulowicz; Peter Schmid-Grendelmeier; Christian Bull; Brigita Sitkauskiene; William B Smith; Elias Toubi; Sonja Werner; Suresh Anné; Janne Björkander; Laurence Bouillet; Enrico Cillari; David Hurewitz; Kraig W Jacobson; Constance H Katelaris; Marcus Maurer; Hans Merk; Jonathan A Bernstein; Conleth Feighery; Bernard Floccard; Gerald Gleich; Jacques Hébert; Martin Kaatz; Paul Keith; Charles H Kirkpatrick; David Langton; Ludovic Martin; Christiane Pichler; David Resnick; Duane Wombolt; Diego S Fernández Romero; Andrea Zanichelli; Francesco Arcoleo; Jochen Knolle; Irina Kravec; Liying Dong; Jens Zimmermann; Kimberly Rosen; Wing-Tze Fan Journal: N Engl J Med Date: 2010-08-05 Impact factor: 91.245
Authors: Matija Rijavec; Peter Korošec; Mira Šilar; Mihaela Zidarn; Jovan Miljković; Mitja Košnik Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: Urs C Steiner; Christina Weber-Chrysochoou; Arthur Helbling; Kathrin Scherer; Peter Schmid Grendelmeier; Walter A Wuillemin Journal: Orphanet J Rare Dis Date: 2016-04-21 Impact factor: 4.123
Authors: Sharton V A Coelho; Naiara M Rust; Lucas Vellasco; Michelle P Papa; Aline S G Pereira; Matheus Ferreira da Silva Palazzo; Maria Aparecida Juliano; Simone M Costa; Ada M B Alves; Marli T Cordeiro; Ernesto T A Marques; Júlio Scharfstein; Luciana B de Arruda Journal: Pharmaceuticals (Basel) Date: 2021-01-12
Authors: P Triggianese; R Senter; A Petraroli; A Zoli; M Lo Pizzo; D Bignardi; E Di Agosta; S Agolini; F Arcoleo; O Rossi; S Modica; E Greco; M S Chimenti; G Spadaro; C De Carolis; M Cancian Journal: Front Med (Lausanne) Date: 2022-09-14
Authors: Stephen Betschel; Jacquie Badiou; Karen Binkley; Rozita Borici-Mazi; Jacques Hébert; Amin Kanani; Paul Keith; Gina Lacuesta; Susan Waserman; Bill Yang; Emel Aygören-Pürsün; Jonathan Bernstein; Konrad Bork; Teresa Caballero; Marco Cicardi; Timothy Craig; Henriette Farkas; Anete Grumach; Connie Katelaris; Hilary Longhurst; Marc Riedl; Bruce Zuraw; Magdelena Berger; Jean-Nicolas Boursiquot; Henrik Boysen; Anthony Castaldo; Hugo Chapdelaine; Lori Connors; Lisa Fu; Dawn Goodyear; Alison Haynes; Palinder Kamra; Harold Kim; Kelly Lang-Robertson; Eric Leith; Christine McCusker; Bill Moote; Andrew O'Keefe; Ibraheem Othman; Man-Chiu Poon; Bruce Ritchie; Charles St-Pierre; Donald Stark; Ellie Tsai Journal: Allergy Asthma Clin Immunol Date: 2019-11-25 Impact factor: 3.406